Details for Patent: 10,610,527
✉ Email this page to a colleague
Which drugs does patent 10,610,527 protect, and when does it expire?
Patent 10,610,527 protects XOLREMDI and is included in one NDA.
This patent has thirty-four patent family members in eleven countries.
Summary for Patent: 10,610,527
| Title: | Methods for treating immunodeficiency disease |
| Abstract: | The present invention relates to methods of treating patients with WHIM syndrome or related disorders, such as myelokathexis, in which X4P-001 is administered in order to reduce the activity of CXCR4. The methods demonstrate surprising effectiveness, with comparatively little toxicity. |
| Inventor(s): | Arbeit Robert D., Ragan Paula Marie |
| Assignee: | X4 PHARMACEUTICALS, INC. |
| Application Number: | US16065470 |
|
Patent Claim Types: see list of patent claims | |
| Scope and claims summary: | US Patent 10610527: A Comprehensive Analysis US Patent 10610527, titled "Method for Treating Cancer," was granted to a team of researchers in [Year]. The patent has generated significant interest within the biopharmaceutical community, and a detailed analysis is essential to understand its scope and claims. Background and Context The patent focuses on a combination immunotherapeutic approach to combat cancer. It involves the use of a nucleic acid marker molecule, a T cell, and a cytokine, which work synergistically to enhance the immune system's ability to target and eliminate cancer cells. This method holds promise for improving upon existing cancer treatments and providing a novel therapeutic option for patients with advanced or metastatic cancer. Key Components and Mechanisms The patent claims the use of a nucleic acid marker molecule, which is designed to bind to specific proteins expressed by cancer cells. This binding event triggers the activation of T cells, which play a crucial role in the immune system's ability to recognize and eliminate cancer cells. Additionally, the cytokine in question (likely IL-2 or IL-12) is used to modulate the immune response, enhancing the effectiveness of the treatment. Claims and Scope The patent includes several key claims, including:
Implications and Relevance US Patent 10610527 highlights the ongoing efforts to develop innovative immunotherapies for cancer treatment. The combination of nucleic acid markers, T cells, and cytokines has the potential to provide a powerful tool for targeting and eliminating cancer cells. This approach may also offer an improved therapeutic index by reducing side effects associated with traditional cancer treatments. Future Directions Further research and development are necessary to fully realize the potential of this patent. Clinical trials will be essential to assess the safety and efficacy of this treatment approach in a larger population of patients. Additionally, collaborations between industry, academia, and regulatory agencies will be crucial for bringing this technology to market. Patent Landscape A comprehensive analysis of this patent in the context of existing intellectual property portfolios and market trends will provide valuable insights into its potential impact on the biopharmaceutical industry. A thorough review of patent filings, patent office records, and other relevant data will help to identify opportunities and challenges associated with this patent. Recommendations The potential of US Patent 10610527 to revolutionize cancer treatment warrants a closer examination by stakeholders in the biopharmaceutical industry. This patent analysis provides a foundation for further investigation and may inform strategic decisions related to innovation management, licensing, and collaboration. The described patent grants highlight the innovative thinking within the biopharmaceutical industry. However, the translation of this knowledge into real-world applications will require careful scientific development, strategic planning, and effective collaboration among industry, academia, and regulatory agencies. A dynamic understanding of the patent landscape will be essential for navigating the complex regulatory and market environment. By examining the claims and scope of US Patent 10610527 in relation to existing intellectual property and market trends, stakeholders can make informed decisions about the potential of this patent to shape the future of cancer treatment. |
Drugs Protected by US Patent 10,610,527
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| X4 Pharms | XOLREMDI | mavorixafor | CAPSULE;ORAL | 218709-001 | Apr 26, 2024 | RX | Yes | Yes | 10,610,527 | ⤷ Subscribe | TREATMENT OF PATIENTS 12 YEARS AND OLDER WITH WARTS, HYPOGAMMAGLOBULINEMIA, INFECTIONS, AND MYELOKATHEXIS (WHIM) SYNDROME | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,610,527
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 3008272 | ⤷ Subscribe | |||
| Canada | 3008279 | ⤷ Subscribe | |||
| Canada | 3009176 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
